NCT07116616 is a Phase 1, PHASE2 clinical trial of mRNA-2808 in Relapsed or Refractory Multiple Myeloma, sponsored by ModernaTX, Inc..

Who is sponsoring NCT07116616?

NCT07116616 is sponsored by ModernaTX, Inc..

What drugs are being tested in NCT07116616?

Interventions in NCT07116616: mRNA-2808.

What condition does NCT07116616 study?

NCT07116616 studies Relapsed or Refractory Multiple Myeloma.

Is NCT07116616 still recruiting?

NCT07116616 is currently recruiting now. Last updated 3 April 2026.

Last reviewed 2026-04-03 · How we verify

NCT07116616

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

Recruiting now Phase 1, PHASE2 Last updated 3 April 2026

What this trial tests

Phase 1, PHASE2 trial testing mRNA-2808 in Relapsed or Refractory Multiple Myeloma in 166 participants. Currently enrolling.

Timeline

30 September 2025

Primary endpoint
17 June 2030

17 June 2032

Quick facts

Lead sponsor	ModernaTX, Inc.
Phase	Phase 1, PHASE2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	166
Start date	30 September 2025
Primary completion	17 June 2030
Estimated completion	17 June 2032
Sites	10 locations across United States

Drugs / interventions tested

mRNA-2808 — full drug profile →

Conditions studied

Relapsed or Refractory Multiple Myeloma — all drugs for Relapsed or Refractory Multiple Myeloma →

Sponsor

ModernaTX, Inc. — full company profile →

Who can join

18 and older, any sex, with Relapsed or Refractory Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the safety and tolerability of mRNA-2808 in participants with relapsed or refractory multiple myeloma (RRMM).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

RNA-Based Therapeutic Strategies in Multiple Myeloma: From Molecular Targets to Delivery and Clinical Translation.
Baranov MV, Shalik I, Tsvetkova A, Streltsova A, et al · · 2026 · cited 1× · PMID 41596492 · DOI 10.3390/ijms27020843

Verify or expand the search:

Other recruiting trials for Relapsed or Refractory Multiple Myeloma

Currently open trials in the same condition.

NCT07369895 — Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
NCT07312188 — A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
NCT06604715 — A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
NCT06574568 — A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
NCT06425991 — A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma · Phase 1 · active not recruiting

Other ModernaTX, Inc. trials

Trials by the same sponsor.

NCT07496450 — A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults · Phase 3 · recruiting
NCT07478952 — A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age · Phase 1 · recruiting
NCT07266558 — A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without Hig · Phase 4 · recruiting
NCT07117487 — A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in · Phase 3 · active not recruiting
NCT07089706 — A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07116616 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by ModernaTX, Inc.
Last refreshed: 3 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07116616.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing